Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Acquired by Jennison Associates LLC

Jennison Associates LLC raised its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 2.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 312,611 shares of the company’s stock after purchasing an additional 6,533 shares during the period. Jennison Associates LLC owned 0.69% of Apogee Therapeutics worth $18,363,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of APGE. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Apogee Therapeutics by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock valued at $94,000 after purchasing an additional 285 shares in the last quarter. Kennedy Capital Management LLC acquired a new position in Apogee Therapeutics during the first quarter valued at approximately $212,000. Allspring Global Investments Holdings LLC purchased a new stake in Apogee Therapeutics during the second quarter worth approximately $143,000. Virtu Financial LLC acquired a new stake in shares of Apogee Therapeutics in the first quarter worth $362,000. Finally, Arizona State Retirement System raised its stake in shares of Apogee Therapeutics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after acquiring an additional 258 shares during the period. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Analyst Ratings Changes

Separately, Wedbush reaffirmed an “outperform” rating and set a $87.00 price target on shares of Apogee Therapeutics in a research report on Tuesday, November 12th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $78.50.

Apogee Therapeutics Trading Up 1.4 %

Shares of APGE stock opened at $43.46 on Friday. The firm has a fifty day simple moving average of $54.29 and a 200-day simple moving average of $48.74. The company has a market capitalization of $1.96 billion, a PE ratio of -17.96 and a beta of 2.93. Apogee Therapeutics, Inc. has a twelve month low of $16.39 and a twelve month high of $72.29.

Insider Buying and Selling at Apogee Therapeutics

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $56.23, for a total value of $2,249,200.00. Following the transaction, the chief executive officer now directly owns 1,354,487 shares of the company’s stock, valued at $76,162,804.01. This represents a 2.87 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Carl Dambkowski sold 6,665 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $47.56, for a total transaction of $316,987.40. Following the sale, the insider now directly owns 280,793 shares of the company’s stock, valued at $13,354,515.08. The trade was a 2.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 114,995 shares of company stock valued at $6,128,295 in the last ninety days. Insiders own 36.10% of the company’s stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.